Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
iCAD, Inc.

iCAD, Inc. (ICAD) Stock Overview

Explore iCAD, Inc.’s financial performance, market position, analyst ratings, and future outlook.

ICAD●NASDAQ
HealthcareMedical - Devices
$3.87
$0.14(3.75%)
U.S. Market opens in 3h 6m

iCAD, Inc. (ICAD)

Meyka AI Score

Z

Key Financials

Market Cap106.3M
P/E Ratio-18.43
EPS (TTM)$-0.19
ROE-0.18%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$4.58

ICAD Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of iCAD, Inc. (NASDAQ: ICAD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, iCAD, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ICAD on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $4.58 for the NASDAQ listing.

Key metrics behind iCAD, Inc.'s NASDAQ-traded stock include a P/E ratio of -18.43 and a market capitalization of 106.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of ICAD on the NASDAQ.

Price Performance (NASDAQ: ICAD)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
-3.01%
6-Month Change
16.57%
Year-to-Date (YTD) Change
94.47%
1-Year Change
130.36%
3-Year Change
13.49%
5-Year Change
-62.97%
All-Time (Max) Change
-90.01%

Contact Information

https://www.icadmed.com
603 882 5200
98 Spit Brook Road, Nashua, NH, 03062

Company Facts

660 Employees
IPO DateDec 13, 1984
CountryUS

Frequently Asked Questions